瓜尼丁-皮佩里丁切换可提供高亲和度小分子NPFF连接体,优先选择NPFF1-R和NPFF2-R亚型
Kareem A Galal1, Samuel Obeng2, Victoria L C Pallares1
1Department of Medicinal Chemistry, College of Pharmacy, The University of Florida, Gainesville, FL, 32610, USA.
European journal of medicinal chemistry
|March 24, 2024
概括
研究人员开发了新的无瓜尼丁Neuropeptide FF (NPFF) 受体连接体,8b和16a. 这些化合物提供了改善的药理动力学特性和亚型选择性,推进了NPFF受体系统研究.
科学领域:
- 药理学 药理学是指药理学的学科.
- 药用化学 医学化学
- 神经科学是一个神经科学.
背景情况:
- 神经FF (NPFF) 受体系统调节阿片类药物的作用,包括阿片类药物诱导的过敏症和耐受性.
- 选择性小分子子的有限可用性阻碍了NPFF受体的药理学探索.
- 现有的NPFF配体,如MES304,通常含有瓜尼丁组,这在体内研究中提出了药理动力学挑战.
研究的目的:
- 设计和合成新的,无关素的NPFF受体连接体.
- 评估这些新配体的结合亲和力,亚型选择性和功能活性.
- 评估这些化合物的潜力,作为改善体内研究的药理学工具.
主要方法:
- 对化合物MES304.4.进行了结构-活性关系 (SAR) 研究.
- 合成了新的piperidine类似物 (8b和16a),消除了关尼丁的功能.
- 实验室试验用于确定NPFF受体结合亲缘关系,亚型选择性 (NPFF1-R与NPFF2-R) 和功能活性 (激动剂/对抗剂).
主要成果:
- 化合物8b和16a证明了对NPFF受体的纳米分子结合亲和力,与MES304.4相比.
- 模拟器8b对NPFF1-R具有15倍的选择性,而16a对NPFF2-R具有8倍的选择性,代表了新的亚型选择性支架.
- 两种类型都没有表现出激素活性;8b在NPFF1-R表现出对抗性质,并且两者都具有有利的体化学特性,有利于体内发育.
结论:
- 强大的,选择性亚型的神经FF受体配体可以在没有瓜尼丁组的情况下被开发出来.
- 新型皮佩里丁类型8b和16a作为创建先进的体内药理学工具的有希望的起点.
- 这些发现为研究NPFF受体系统在各种生理过程中的作用开辟了新的途径.
相关概念视频
Ligand-Gated Ion Channel Receptor: Gating Mechanism
2.2K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
2.2K
GPCR Desensitization
6.0K
G protein-coupled receptor (GPCR) signaling plays a crucial role in cell functioning. GPCR desensitization is an equally essential process. It allows cells to respond to changing environments and regain sensitivity to new stimuli while preventing unnecessary stimulation when no longer needed. Prolonged exposure to stimuli leads to GPCR desensitization. It involves blocking the receptors from binding and activating additional G proteins. This inhibits activation of downstream effectors, thereby...
6.0K
The Two-State Receptor Model
1.9K
The two-state receptor model explains a drug's interaction with receptors, such as G protein-coupled receptors and ligand-gated ion channels, to induce or inhibit a biological response. When no natural ligands are present, a receptor exists in an equilibrium of inactive (Ri) and active (Ra) conformations. The inactive form does not produce a response, while the active form generates a basal effect known as constitutive activity.
The binding affinity of a drug determines its interaction with...
The binding affinity of a drug determines its interaction with...
1.9K
Basicity of Heterocyclic Aromatic Amines
6.0K
Heterocyclic amines, where the N atom is a part of an alicyclic system, are similar in basicity to alkylamines. Interestingly, the heterocyclic amine having a nitrogen atom as part of an aromatic ring has much less basicity than its corresponding alicyclic counterpart. For this reason, as presented in Figure 1, piperidine (pKb = 2.8) is significantly more basic than pyridine (pKb = 8.8).
6.0K
G-protein Coupled Receptors
118.6K
G-protein coupled receptors are ligand binding receptors that indirectly affect changes in the cell. The actual receptor is a single polypeptide that transverses the cell membrane seven times creating intracellular and extracellular loops. The extracellular loops create a ligand specific pocket which binds to neurotransmitters or hormones. The intracellular loops holds onto the G-protein.
118.6K
Drug-Receptor Interaction: Agonist
2.5K
Agonists are drugs that interact with specific receptors in the body to produce a biological response. When an agonist binds to a receptor, it activates or enhances the receptor's function, leading to physiological effects. The interaction between agonist drugs and receptors is crucial for their therapeutic action in various medical treatments.
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
Agonists can bind to receptors in different ways. Some agonists bind directly to the receptor's active site, mimicking the endogenous...
2.5K


